Hepatitis C beware-the end is nigh

The Lancet

Volumn 384, Issue 9954, 2014, Pages 1557-1560

  Gane, Ed ^a,b  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASUNAPREVIR; BOCEPREVIR; DACLATASVIR; DASABUVIR; GS 5816; LEDIPASVIR; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; VEDROPREVIR; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE; ISOQUINOLINE DERIVATIVE; SULFONAMIDE;

AGING; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; COST EFFECTIVENESS ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; GENETIC POLYMORPHISM; GENOTYPE; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER FAILURE; NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REIMBURSEMENT; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS MUTATION; FEMALE; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MALE;

ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; ISOQUINOLINES; MALE; SULFONAMIDES;

EID: 84924975080     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61225-3     Document Type: Note

References (29)

1. Hanafiah K, Groeger J, Flaxman A, Wiersma S. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333-42.
2. Davis G, Alter M, El-Serag H, et al. Aging of HCV infected persons in US: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010;138:513-21.
3. Razavi H, Waked I, Sarrazin C, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 2014;21(suppl 1):34-59.
4. North C, Hong BA, Adewuyi S, et al. Hepatitis C treatment and SVR: the gap between clinical trials and real-world treatment aspirations. Gen Hosp Psychiatry 2013;35:122-28.
5. Hezode C, Fontaine H, Dorival C, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014;147:132-42.
6. Foster G, Hezode C, Bronowicki J-P, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011;141:881-89.
7. Lok A, Gardiner D, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012;366:216-24.
8. Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5a inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C Virus genotype 1b-infected null responders. Hepatology 2012;55:742-48.
9. Manns M, Pol S, Jacobson IM, et al, on behalf of the HALLMARK-DUAL Study Team. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014; published online July 28. http://dx.doi.org/10.1016/S0140-6736 (14) 61059-X.
10. Lok AS, Gardiner DF, Hezode C, et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol 2014;60:490-99.
11. Vierling JM, Lataillade M, Gane EJ, et al. Sustained virologic response (SVR12) in HCV genotype 1 patients receiving peginterferon lambda in combination with ribavirin and either daclatasvir or asunaprevir: interim results from the D-LITE study. Hepatology 2012;56:1522-23.
12. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon or ribavirin and treatmentnaive patients: the COSMOS randomised study. Lancet 2014; published online July 28. http://dx.doi.org/10.1016/S0140-6736 (14) 61036-9.
13. Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014;146:1669-79.
14. Lenz O, Fevery B, Verbinnen T, et al. Resistance analyses of HCV isolates from patients treated with simeprevir in phase IIB/III studies. Hepatology 2013;58(suppl 1):1101 (abstr).
15. American Association for the Study of Liver Disease, Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. 2014. http://www.hcvguidelines.org/full-report-view (accessed July 21, 2014).
16. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C. April, 2014. http://files.easl.eu/easlrecommendationson-treatment-of-hepatitis-C.pdf (accessed July 21, 2014).
17. Jacobson IM, Ghalib RH, Rodriguez-Torres M, et al. SVR results of a oncedaily regimen of simeprevir (SMV, TMC435) plus sofosbuvir (SOF, GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: the COSMOS study. Hepatology 2013;58:LB-3 (abstr).
18. Hagan LM, Sulkowski MS, Schinazi RF. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon ineligible/intolerant individuals. Hepatology 2014;60:37-45.
19. Kowdley K, Gordon S, Reddy R, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879-88.
20. Afdhal N, Reddy R, Nelson D, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-93.
21. Feld J, Kowdley K, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1594-603.
22. Zeuzem S, Jacobson I, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1604-14.
23. Everson G, Tran T, Towner W, et al. Safety and efficacy of treatment with the interferon-free, ribavirin-free combination of sofosbuvir + GS-5816 for 12 weeks in treatment-naïve patients with genotype 1-6 HCV infection. J Hepatol 2014;60:S46.
24. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998;282:103-07.
25. Chu T, Kulkarni R, Gane EJ, et al. Effect of IL28B genotype on early viral kinetics during interferon-free treatment (INFORM-1) of patients with chronic hepatitis C. Gastroenterology 2012;142:790-95.
26. Guedj J, Dahari H, Rong L, et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci 2013;110:3991-96.
27. Kohli A, Sims Z, Marti M, et al. Combination oral, ribavirin free, antiviral therapy to optimize treatment outcomes for hepatitis C GT-1 treatment naïve patients: interim results from the NIAID SYNERGY trial. 64th Annual Meeting of the American Association for the Study of Liver Diseases; Washington, DC, USA; Nov. 1-5, 2013. Abstract LB8.
28. Wedemeyer H, Duberg AS, Buti M, et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 2014;21(suppl 1):60-89.
29. Sievert W, Altraif I, Razavi H, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011;31(suppl 2):61-80.